Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
Donanemab is a targeted antibody drug which slows the early stages of Alzheimer’s. Alzheimer’s Research UK said Nice's announcement “risks signalling that the UK is no longer a good place to ...
Results that may be inaccessible to you are currently showing.